Connect with the future of healthcare
Open Stent Solution develops the Cornelis™ Valve, the world’s first valvular implant employing RIBBON VALVE technology for non-surgical heart valve replacement, targeting mitral and tricuspid valve regurgitation, to restore heart valve continence and to TREAT heart valve dysfunction. This innovative method offers a less invasive alternative, promising faster recovery and reduced risk compared to traditional surgery.
Prototype/preclinical
7.500.000€
2027
Medical devices
6.25%
500€
Share this project on your website.
Copy and paste the following code into your content.
Open Stent Solution (OSS) stands at the forefront of minimally invasive heart valve replacement technology, with its groundbreaking Ribbon Valve technology aimed at treating heart valve diseases. Specializing in transcatheter valve replacement, OSS is dedicated to providing innovative, patient-adaptive solutions with the Cornelis valve device, aimed at a wide patient demographic.
Currently, OSS is advancing towards finalizing the Cornelis Valve™ design and moving into the verification, validation, and preclinical trial phases by the third quarter of 2024. The Cornelis™ Valve, designed as a direct replacement for failing heart valves, has demonstrated promising hemodynamic performance and integration within the anatomical heart structures in animal trials, aiming to halt disease progression, enhance quality of life, and extend patient longevity.
With mitral regurgitation—a condition affecting a significant portion of the elderly population—remaining largely untreated due to surgical limitations, OSS targets a potential $18 billion TMVR market by 2032. The company’s innovative approach overcomes the design and anatomical limitations of current technologies, offering a solution for a broader patient base.
OSS’s strategy involves finalizing its product design, engaging with regulatory bodies like the FDA, and initiating clinical trials to achieve global regulatory approvals. Through strategic partnerships with leading heart valve specialists and MedTech companies worldwide, OSS is well-positioned to expedite its market entry and adoption.
Focused on developing treatments for both mitral and tricuspid valve diseases, OSS is committed to expanding access to its technologies, leveraging its expertise to bring these much-needed solutions to patients. With significant seed funding, prestigious awards, and a growing team of experts, OSS is poised to make substantial contributions to the field of heart valve replacement, revolutionizing patient care with its unique, adaptable valve technology.
Open Stent is a game-changer for heart health, targeting a common heart condition that affects 7 million older adults in Europe, the United States, and China. Currently, many patients do not receive the best treatment because traditional heart surgery is too risky for them, and existing heart devices do not fit well for most people, putting their safety at risk.
Open Stent's innovative solution: a unique heart valve that can be adjusted for any patient, designed to be placed through a simple procedure from the groin, and without open-heart surgery. This new design can match any blood vessel size and heart movement of the patient, promising better outcomes. With successful early animal tests and plans for more studies starting in 2025, Open Stent is on track to meet a significant need in heart care.
Led by a team of expert cardiac surgeons, Open Stent arises to meet a clear medical need drawn directly from the experiences of doctors and patients.
Regulatory hurdles could delay or restrict Open Stent's market access, with the outcome of human clinical trials being a crucial turning point.
Moreover, although there is currently no known competitor with an approach as innovative as Open Stent's to address this significant unmet medical need, new competitors with similar features may emerge.
Already have an account? Please login here .